A long noncoding RNA GTF2IRD2P1 suppresses cell proliferation in bladder cancer by inhibiting the Wnt/β-catenin signaling pathway

Zhuo Huang1,*, Hongbin Gao1,2,*, Liangliang Qing1, Biao Wang1, Chaoyong He1, Ning Luo1, Chuncheng Lu1, Shipeng Fan1, Peng Gu1,2 and Hui Zhao1,2

1 Department of Urology, First Affiliated Hospital of Kunming Medical University, Kunming Medical College, Kunming, Yunnan, People’s Republic of China
2 Clinical Research Center for Chronic Kidney Disease, First Affiliated Hospital of Kunming Medical University, Kunming Medical College, Kunming, Yunnan, People’s Republic of China
* These authors contributed equally to this work.

ABSTRACT

Background: There is growing evidence that long non-coding RNAs (LncRNAs) are key in the development of a variety of human tumors. However, the role of lncRNA GTF2IRD2P1 has not been well studied in cancer. The impact of GTF2IRD2P1 on the biological function and clinical relevance in bladder cancer is largely unknown. This study aimed to investigate the biological role of GTF2IRD2P1 in bladder evolution and carcinogenesis.

Methods: We used bioinformatics to obtain the lncRNA GTF2IRD2P1 from bladder urothelial carcinoma (BLCA) in The Cancer Genome Atlas (TCGA) database. The expression of lncRNA GTF2IRD2P1 was detected by qRT-PCR. The CCK8 assay and flow cytometry were used to detect the lncRNA GTF2IRD2P1 function on the proliferation of bladder cancer cells. A western blot was used to calculate the protein level of cell cycle proteins and Wnt signaling pathway proteins. The effect of lncRNA GTF2IRD2P1 on tumorigenesis of bladder cancer was confirmed by a xenograft nude mouse model.

Results: GTF2IRD2P1 expression was found to be lower in both human bladder cancer tissues and cell lines (UM-UC-3, RT4, and 5637), and elevated in T24 compared to the corresponding normal controls. GTF2IRD2P1 expression was also enhanced after transfection of UM-UC-3 cells with the overexpression vector. Meanwhile, overexpression of GTF2IRD2P1 inhibited the proliferation of UM-UC-3 and prolonged the cell cycle. The silencing of GTF2IRD2P1 significantly increased the proliferation and shortened the cell cycle of T24 cells and induced Wnt signaling activity to promote the progression of bladder cancer. Similarly, the transplanted tumor nude mouse model demonstrated that silencing GTF2IRD2P1 strengthens the progression of bladder cancer by targeting the Wnt signaling pathway.

Subjects  Bioinformatics, Cell Biology, Genomics, Oncology, Urology
Keywords  Bladder cancer, Long noncoding RNA, Cell cycle, Proliferation, Signaling pathway
INTRODUCTION

Bladder cancer (BCa) is among the ten most common types of cancer in the world, the fourth most common malignancy in men, and one of the most common malignancies in women (Richters, Aben & Kiemeney, 2020; Lenis et al., 2020). Globally, there are approximately 550,000 new cases each year, of which roughly 200,000 patients die (Bray et al., 2018). Despite significant advances in clinical therapies such as surgery, chemotherapy, and radiation therapy over the past few decades, the 5-year survival rate for BCa patients remains low (Humphrey et al., 2016; Alfred Witjes et al., 2017; Babjuk, 2017; Nadal & Bellmunt, 2019; Knowles & Hurst, 2015). The lack of early diagnosis and effective treatment may result in a poor clinical prognosis for BCa patients (Carneiro et al., 2015). Therefore, the discovery of novel BCa target molecules is of great clinical importance for the treatment of BCa.

Long non-coding RNAs (lncRNAs) are defined as non-coding RNAs with at least 200 nucleotides that do not encode proteins (Bunch, 2018). LncRNA plays an important role in regulating the multiple physiological activities of cells (Xie et al., 2017). Many studies have shown the abnormal expression of lncRNAs in tumors, and thus they are potential therapeutic targets for some cancers (Liang et al., 2020; Zha et al., 2021; Long et al., 2021; Li et al., 2020). LncRNA may be used for therapeutic targeting and as a reliable diagnostic and predictive factor for the survival and tumor recurrence in patients with bladder tumors (Quan et al., 2018; He et al., 2019). The occurrence and progression of malignant tumors can be regulated by lncRNAs in a variety of ways. For example, the competitive adsorption of miR-132 by lncRNA SNHG5 through sponge function, which regulates SOX4 expression, contributes to the development of cervical cancer (Zhang et al., 2021). The lncRNA DNAJC3-AS1 regulates fatty acid synthase through the EGFR pathway, thereby promoting colorectal cancer progression (Tang et al., 2020). LncRNA PCAT1 can interact with DKC1 to activate the VEGF/AKT/Bcl-2/caspase9 pathway, thereby regulating non-small cell lung cancer (NSCLC) cell proliferation, invasion, and apoptosis (Liu et al., 2021). A variety of lncRNAs have been reported to play critical role in BCa biology, including lncRNA MAFG-AS1, lncRNA SLC16A1-AS1 and lncRNA SNHG1 (Tang et al., 2021; Logotheti et al., 2020; Xu et al., 2020). However, the role of lncRNAs in BCa are relatively unknown, specifically that of lncRNA GTF2IRD2P1.

We obtained the lncRNA GTF2IRD2P1, which is one of the most significantly expressed lncRNAs in BCa samples, using bioinformatic analysis of The Cancer Genome Atlas (TCGA) database. We then used survival analysis to determine that GTF2IRD2P1 was a highly expressed lncRNA with a very significant protective effect on the overall survival (OS) of BCa patients. Finally, we used Gene Set Enrichment Analysis (GSEA) to predict the possible involvement of GTF2IRD2P1 in the Wnt signaling pathway. We validated our prediction by exploring the role of lncRNA GTF2IRD2P1 in BCa cells and the downstream Wnt pathway by performing gain and loss of function of lncRNA GTF2IRD2P1. Our findings indicate that elevated lncRNA GTF2IRD2P1 significantly inhibited Wnt signaling. The results of this study suggest that lncRNA GTF2IRD2P1
downregulation promotes BCa development through activation of the Wnt signaling pathway.

**MATERIALS AND METHODS**

**Bioinformatics analysis based on TCGA BLCA dataset**

We downloaded the RNA-seq expression matrix and clinical data of TCGA-BLCA from UCSC’s Xena database (https://xenabrowser.net/datapages/) to screen for lncRNAs that are differentially expressed in BCa patients using the detection platform polyA+ IlluminaHiSeq. The TCGA-BLCA cohort was comprised of 426 cases (19 cases of normal bladder tissue, 407 cases with tumor tissue of BCa origin). Additional details may be found from the portal. We then analyzed the expression correlation of 20,530 genes in the TCGA-BLCA expression matrix with GTF2IRD2P1 by using the psych package in R language with the statistical method Pearson correlation and the Pearson product-moment correlation coefficient. GSEA analysis was performed using the cluster profile package, and the gene set data was downloaded from misgdb using the cancer gene set (https://www.gsea-msigdb.org/gsea/msigdb/index.jsp). Thus, we created the hallmark feature gene set (h. all. V 7.2. Entrez. gmt).

**Clinical sample**

We acquired thirty BCa tumor tissue samples with the corresponding adjacent normal tissue (5 cm from the edge of the cancerous tissue) from patients undergoing surgery at the First Affiliated Hospital of Kunming Medical University between October 2018 and June 2021. Written informed consent was obtained from each patient according to committee policy. A diagnosis of uroepithelial carcinoma was independently confirmed by two pathologists in all specimens. Ethical consent was approved by the Human Research Ethics Review Committee of the First Affiliated Hospital of Kunming Medical University (approval number: (2021) Lunshen L No. 33).

**Extraction of RNA and the qRT-PCR**

The extraction of the total RNA from BCa tissues and cell lines was performed using a TRIzol kit (Thermo Fisher Scientific, Waltham, MA, USA), followed by cDNA synthesis using the Reverse Transcription Kit (GeneCopoeia, Guangzhou, China). Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted using BeyoFast™ SYBR Green qPCR Mix (Bio-Rad, Shanghai, China) based on the manufacturer’s guidelines. The primer sequences were as follows: 5′-GGATACGGTGCCCACGA-3′, 3′-TTTC AAGACATAAGCTGACCAGCTT-5′. GAPDH: 5′-ACAGCCTCAGATCAGTCAGC-3′, 3′-TAGCACCCTCTGAGTACTGG-5′. GAPDH was applied as an internal control for gene expression standardization. All reactions were performed in triplicate and relative gene expression was calculated using the $2^{-\Delta\Delta Ct}$ method.

**Western blotting**

We extracted total proteins from cells, animal tissues and human tissue specimens, respectively, and determined protein concentrations using a BCA kit (Beyoncé, Shanghai,
China). Total proteins were solubilized using RIPA lysis buffer (Beyoncé, Shanghai, China) containing various protease inhibitors. The total protein was separated by SDS-PAGE and was transferred to PVDF membranes (Millipore, Burlington, MA, USA) by electroblotting. The membranes were blocked with 5% skimmed milk for 1 h at room temperature. The membranes were incubated overnight at 4 °C with specific primary antibodies. The membrane then was incubated with the secondary antibody at room temperature for 2 h and was detected with an ultrasensitive ECL chemiluminescence kit (New Saimei, Suzhou, China) and imaged with a chemiluminescence imaging system (Shanghai Tennant, Shanghai, China). The primary antibodies were as follows: Cyclin A2 (#18202-1-AP; Proteintech, Wuhan, China), Cyclin D1 (#60186-1-Ig; Proteintech, Wuhan, China), β-catenin (#51067-2-AP; Proteintech, Wuhan, China), TCF4 (#GR3295722-2; Proteintech, Kunming, China), E-cadherin (#20874-1-AP; Proteintech, Wuhan, China), Anti-mouse IgG (H+L) (#14709; CST, Parsons, KS, USA), Anti-rabbit IgG (H+L) (#14708; CST, Parsons, KS, USA), GAPDH mouse-derived (#60004-1-Ig; Proteintech, Wuhan, China), and GAPDH rabbit source (#10494-1-AP; Proteintech, Wuhan, China).

**Cell culture**
We purchased four BCa cell lines (5637, RT4, T24 and UM-UC-3) and the standard bladder cell line SV-HUC-1 from the American Typical Culture Collection (ATCC). All were simultaneously cultured in RPMI-1640 medium and F-12K medium with 10% fetal bovine serum (FBS) and 1% dual antibody (P/S) as recommended by the manufacturer. These cells were then cultured in a humidified incubator at 37 °C with 5% CO₂.

**Lentiviral packaging and vector construction**
The pLVX-puro-GTF2IRD2P1 group and the lentivirus negative control group (pLVX-puro) were determined to be the overexpression groups; the pLVX-shGTF2IRD2P1-1-puro group, the pLVX- shGTF2IRD2P1-2-puro group, and the lentivirus negative control group (pLVX-shRNA2-puro) were the low expression groups and were purchased from Acura Biotechnology (Hunan, China). We synthesized the GTF2IRD2P1 sequence and subcloned it into plasmids pLVX-IRES-ZsGreen1 and pLVX-shRNA2-puro to obtain the overexpression and low expression group plasmids, respectively. Each plasmid was then packaged with lentivirus. Transfection was performed with the Liposome 2000 reagent (ThermoFisher Scientific, Waltham, MA, USA) based on the manufacturer’s protocol.

**The cell growth test**
The assay for cell proliferation was determined using the Cell Counting Kit 8 (CCK-8). Cells were inoculated into 96-well plates with 5 × 10⁵ cells per well in triplicate. Ten microliters of CCK-8 reagent were added to each well at 0, 24, 48, and 72 h and incubated in a CO₂ incubator for 2 h. The absorbance was measured at 450 nm. All experiments were repeated at least three times.
Analysis of the cell cycle
The resulting cells were digested with pancreatic protease and immobilized in 75% ethanol at 4 °C for up to 24 h. The supernatant was discarded by centrifugation and incubated for 1 h with PI staining solution containing RNAase A. The cycle of the cells was subsequently detected by flow cytometry (Eisen, Lansing, MI, USA). The experiment was repeated three times.

Nude mice tumorigenesis assay
A total of 12 BALB/c nude mice, between 5 to 6 weeks old, were provided by Hunan Sleek Jingda Laboratory Animal Co. (Changsha, China). The mice were divided into two groups. In the LV-NC groups, T24 cells (5 × 10⁶) infected with lentivirus were subcutaneously inoculated into the armpits of mice as a negative control group (n = 6). In the LV-shRNA group, T24 cells infected with Lv-shGTF2IRD2P1-2 were inoculated into remaining mice using the same procedure. The volume (V) of the tumor was obtained as follows: 
V = (ab²)/2, with “a” indicating the long diameter of the tumor and “b” indicating the short diameter of the tumor. All experiments concerning animals were carried out following the guidelines for animal experiments approved by the Laboratory Animal Ethics Committee of Kunming Medical University.

An analysis of statistics
Statistical analysis was performed using SPSS 23.0 and GraphPad Prism 8 software. Survival curves were calculated using the Kaplan-Meier method and p-values were calculated using the log-rank test. Two independent groups were analyzed using the t-test if the data conformed to a normal distribution and the Mann-Whitney rank-sum test or the Kolmogorov-Smirnov test if the data did not conform to a normal distribution. All data were expressed as mean ± SEM or SD, and p < 0.05 was considered statistically significant.

RESULTS
Identification of key BCa IncRNAs based on TCGA and analysis of pathway enrichment based on the KEGG and GSEA
We imported the TCGA-BLCA expression matrix into R and analyzed it using the limma toolkit to obtain 30 IncRNAs that were significantly up-regulated (logFC > 1, p.adj < 0.05) and 36 IncRNAs that were significantly down-regulated (logFC < −1, p.adj < 0.05). The volcano (Fig. 1A) and heat map (Fig. 1B) differences show the distribution of IncRNA. One-way Cox regression analysis of the 66 IncRNAs was then performed using R survival and survminer packages with a set minimum threshold between the two sets of cutoffs at 0.2. The accompanying table of clinical survival characteristics was downloaded from the Xena database at UCSC (https://xenabrowser.net/datapages/). We used the overall survival time (OS.time) data, as well as OS survival event data to correlate with the expression of relevant IncRNAs. Ultimately 36 of 66 IncRNAs were associated with overall survival in BLCA patients (Fig. 1C), and the five most statistically significant (p < 0.0001) IncRNAs were SNHG10, NSUN5P2, PSORS1C3, GTF2IRD2P1, and RAET1K (Table 1).
Figure 1 Identification of key BCa IncRNAs based on the TCGA and its analysis of pathway enrichment based on the KEGG and GSEA. (A and B) Volcano plot and heat plot differentially demonstrate the distribution of IncRNAs. (C) Cox regression analysis of single factors for differentially
GTF2IRD2P1 was found to be one of the most significant molecules associated with overall survival in BCa. Its co-expressed genes were able to significantly negatively enrich the BCa pathway of the Kyoto Encyclopedia of Genes and Genomes (KEGG) ($p_{\text{adjust}} < 0.05$, enrichment score $= -0.503$) (Fig. 1F). Box plot analysis showed that the expression level of GTF2IRD2P1 was significantly lower in tumor tissues than in normal tissues adjacent to cancerous tissues (Fig. 1D). In addition, low-GTF2IRD2P1 expressing patients had a significantly worse prognosis than high-expressing patients according to Kaplan Meier analysis (Hazard Ratio $< 1$, $p < 0.001$) (Fig. 1E). Lastly, we used GSEA to predict the possible involvement of GTF2IRD2P1 in the Wnt signaling pathway (Fig. 1G).

Relationship of GTF2IRD2P1 with the clinicopathological features of BCa patients

BCa patients were divided into low- and high-GTF2IRD2P1 expression groups according to the median expression value of GTF2IRD2P1 (0.47). The findings from this analysis, summarized in Table 2, showed that GTF2IRD2P1 expression was associated with tumor grading ($p = 0.01$). In contrast, no correlation was found between GTF2IRD2P1 expression and other features, including age, gender, smoking, tumor size and lymph node metastasis (all $p > 0.05$).

GTF2IRD2P1 is downregulated in BCa tissues and expressed in cell lines

We measured the expression of GTF2IRD2P1 in cancer and paraneoplastic tissues from 30 BCa patients using by RT-qPCR to further validate our findings. The results showed that the expression of GTF2IRD2P1 in BCa tissues was significantly lower than that in normal tissues adjacent to cancer (Fig. 2A). A significant downregulation of GTF2IRD2P1 expression in neoplastic tissues was observed compared to the neighboring normal tissues. Therefore, we used RT-qPCR to validate the expression levels of GTF2IRD2P1 in the standard bladder cell line SV-HUC-1 and BCa cell lines standardized by GAPDH. Four BCa cell lines (5637, RT4, UM-UC-3 and T24) had different levels of GTF2IRD2P1 expression compared to SV-HUC-1. GTF2IRD2P1 had a significantly lower expression in BCa cell lines (5637 and UM-UC-3) vs SV-HUC-1, while the opposite was true for the BCa cell line T24 (Fig. 2B). In addition, protein expression of β-catenin, a key protein in the Wnt signaling pathway, was significantly upregulated in BCa tissues compared to the corresponding adjacent normal bladder tissues (Fig. 2C).
| Gene symbol | p.val   | Hazard ratio   | 95% CI     |
|-------------|---------|----------------|------------|
| SNHG10      | 3.62E−06| Hazard Ratio = 0.75 | 95% CI [0.62–0.9] |
| NSUN5P2     | 4.11E−06| Hazard Ratio = 0.74 | 95% CI [0.64–0.85] |
| PSORS1C3    | 2.75E−05| Hazard Ratio = 0.86 | 95% CI [0.79–0.93] |
| GTF2IRD2P1  | 6.33E−05| Hazard Ratio = 0.8  | 95% CI [0.71–0.91] |
| RAET1K      | 6.70E−05| Hazard Ratio = 0.87 | 95% CI [0.78–0.98] |
| NSUN5P1     | 0.000264| Hazard Ratio = 0.76 | 95% CI [0.66–0.88] |
| CDRI        | 0.000292| Hazard Ratio = 1.2  | 95% CI [1.1–1.4] |
| SNHG12      | 0.000335| Hazard Ratio = 0.8  | 95% CI [0.66–0.97] |
| GTF3P       | 0.000443| Hazard Ratio = 0.91 | 95% CI [0.85–0.97] |
| FLJ12825    | 0.000516| Hazard Ratio = 0.87 | 95% CI [0.78–0.95] |
| GHRLOS      | 0.000625| Hazard Ratio = 0.84 | 95% CI [0.74–0.95] |
| PI4KAP1     | 0.001166| Hazard Ratio = 0.95 | 95% CI [0.85–1.1] |
| MAL2        | 0.001795| Hazard Ratio = 0.92 | 95% CI [0.86–0.99] |
| C9orf163    | 0.003252| Hazard Ratio = 0.87 | 95% CI [0.76–0.99] |
| NAP1L6      | 0.003969| Hazard Ratio = 1.1  | 95% CI [1–1.2] |
| GGT3P       | 0.005117| Hazard Ratio = 0.88 | 95% CI [0.8–0.98] |
| EMX2OS      | 0.009028| Hazard Ratio = 0.96 | 95% CI [0.92–1] |
| PGM5P2      | 0.009365| Hazard Ratio = 1.1  | 95% CI [0.94–1.2] |
| SCARNA12    | 0.011053| Hazard Ratio = 0.83 | 95% CI [0.72–0.96] |
| UCA1        | 0.011565| Hazard Ratio = 0.97 | 95% CI [0.93–1] |
| PI4KAP2     | 0.012413| Hazard Ratio = 0.97 | 95% CI [0.88–1.1] |
| PYY2        | 0.012543| Hazard Ratio = 0.95 | 95% CI [0.86–1] |
| HSD17B7P2   | 0.014204| Hazard Ratio = 0.86 | 95% CI [0.74–1] |
| RRN3P1      | 0.014234| Hazard Ratio = 0.95 | 95% CI [0.87–1] |
| MST1P2      | 0.014882| Hazard Ratio = 0.91 | 95% CI [0.82–1] |
| PVT1        | 0.019039| Hazard Ratio = 1.1  | 95% CI [0.95–1.2] |
| HCG22       | 0.019975| Hazard Ratio = 1.1  | 95% CI [0.96–1.2] |
| C2orf48     | 0.021824| Hazard Ratio = 0.96 | 95% CI [0.87–1.1] |
| GEMIN8P4    | 0.022421| Hazard Ratio = 1.2  | 95% CI [0.96–1.4] |
| RG55        | 0.030152| Hazard Ratio = 1.1  | 95% CI [0.96–1.2] |
| RRN3P2      | 0.032292| Hazard Ratio = 0.9  | 95% CI [0.79–1] |
| HYMAI       | 0.034247| Hazard Ratio = 1.1  | 95% CI [0.98–1.3] |
| DGCR5       | 0.044556| Hazard Ratio = 0.94 | 95% CI [0.87–1] |
| SNORD1C     | 0.04538 | Hazard Ratio = 0.95 | 95% CI [0.83–1.1] |
| SNHG3       | 0.045721| Hazard Ratio = 0.92 | 95% CI [0.78–1.1] |
| SNHG1       | 0.048441| Hazard Ratio = 0.89 | 95% CI [0.72–1.1] |

Notes:
A total of 36 of 66 lncRNAs were associated with overall survival in BCa patients, and the five most statistically significant (p < 0.0001) lncRNAs were SNHG10, NSUN5P2, PSORS1C3, GTF2IRD2P1, and RAET1K. BCa, bladder cancer; lncRNAs, long noncoding RNAs.
Effect and role of GTF2IRD2P1 in cell proliferation and cell cycle by in vitro experiments

In UM-UC-3 and T24 cells, the effect of GTF2IRD2P1 overexpression (GTF2IRD2P1 OE) and GTF2IRD2P1 knockdown were analyzed by CCK8 and flow cytometry for the proliferation and cycling of BCa cells. Figure 3A shows the overexpression treatment of GTF2IRD2P1 that significantly promoted GTF2IRD2P1 expression compared to the vector ($p < 0.0001$). Treatments that knocked down both targets of GTF2IRD2P1 significantly inhibited GTF2IRD2P1 expression compared to the negative control (NC) ($p < 0.01$). In addition, CCK8 experiments showed that GTF2IRD2P1 OE inhibited the proliferation of BCa cells. However, GTF2IRD2P1 knockdown promoted BCa cell proliferation (Fig. 3B). Flow cytometry analysis also showed that GTF2IRD2P1 OE significantly enhanced cell cycle arrest, and GTF2IRD2P1 knockdown attenuated cell cycle arrest (Fig. 3C). We examined the protein levels of key components in the cell cycle after GTF2IRD2P1 OE and GTF2IRD2P1 knockdown to further reveal the critical role of GTF2IRD2P1 in the cell cycle. Western blot analysis showed that GTF2IRD2P1 overexpression downregulated Cyclin A2 and Cyclin D1 protein levels in UM-UC-3 cells. However, the knockdown of GTF2IRD2P1 upregulated the protein levels of Cyclin A2 and Cyclin D1 in T24 cells (Fig. 3D). Taken together, the above results suggests that changes in

### Table 2: Relationship of GTF2IRD2P1 with the clinicopathological features of BCa patients.

| Features                        | Total no. n = 30 | GTF2IRD2P1 expression | p values |
|---------------------------------|------------------|-----------------------|----------|
|                                 |                  | Low (n = 15)          | High (n = 15) |           |
| Age (years)                     |                  |                       |           |
| ≤65                             | 16               | 8                     | 8         | 0.372    |
| >65                             | 14               | 7                     | 7         |          |
| Gender                          |                  |                       |           |
| Female                          | 6                | 2                     | 4         | 0.999    |
| Male                            | 24               | 13                    | 11        |          |
| Smoking                         |                  |                       |           |
| No                              | 10               | 4                     | 6         | 0.999    |
| Yes                             | 20               | 11                    | 9         |          |
| Tumor size (cm)                 |                  |                       |           |
| ≤3                              | 21               | 11                    | 10        | 0.669    |
| >3                              | 9                | 4                     | 5         |          |
| Lymph node metastasis           |                  |                       |           |
| No                              | 28               | 13                    | 15        | 0.999    |
| Yes                             | 2                | 2                     | 0         |          |
| Tumor grading                   |                  |                       |           |
| Low                             | 9                | 1                     | 8         | 0.010    |
| High                            | 21               | 14                    | 7         |          |

Notes:
- GTF2IRD2P1 expression was associated with tumor grading ($p = 0.01$). However, no correlation was found between GTF2IRD2P1 expression and other features, including age, gender, smoking, tumor size, and lymph node metastasis (all $p > 0.05$).
- BCa, bladder cancer.
GTF2IRD2P1 expression cause corresponding changes in cell proliferation and cell cycle in in vitro experiments.

Effect and role of GTF2IRD2P1 in cell proliferation and cell cycle by in vivo experiments

We confirmed the regulation of BCa development in vivo by GTF2IRD2P1 using a T24 cell nude mouse xenograft model. The LV-NC group and the LV-shGTF2IRD2P1-2 group were inoculated with T24 cells, respectively. The tumors were dissected as shown in Fig. 4A. In terms of tumor phenotype, LV-shGTF2IRD2P1-2 promoted tumor growth, and GTF2IRD2P1 knockdown significantly increased the weight and volume of the tumor (Fig. 4B). Meanwhile, the differential expression levels of GTF2IRD2P1 in nude mouse tumors were detected by qRT-PCR (Fig. 4C). The level of cyclin D1, a cell cycle protein, was analyzed by Western blot in nude mouse tumors (Fig. 4D). Thus, these data suggest that the low expression of GTF2IRD2P1 promoted cell proliferation and cell cycle protein expression in in vivo experiments.

GTF2IRD2P1 negatively regulates the Wnt signaling pathway

The critical role of GTF2IRD2P1 in the Wnt signaling pathway for BCa progression was demonstrated. We examined the expression levels of key protein molecules in the Wnt
Figure 3 Effect of GTF2IRD2P1 on proliferation and cell cycle of BCa cells by in vitro assay. (A) Validation of the expression efficiency of GTF2IRD2P1. (B) CCK8 assay to detect the influence of GTF2IRD2P1 on the proliferation of BCa cells. (C) Flow cytometric analysis of the impact of GTF2IRD2P1 on BCa cell cycle. (D) Western blot to detect the expression of cell cycle proteins. Not significant (NS), \( p^* < 0.05 \), \( p^{**} < 0.01 \), \( p^{***} < 0.001 \), \( p^{****} < 0.0001 \). BCa, bladder cancer.
signaling pathway following GTF2IRD2P1 overexpression and GTF2IRD2P1 silencing in UM-UC-3 and T24 BCa cell lines, respectively, and we also validated it in in vivo animal experiments. Western blotting analysis showed that GTF2IRD2P1 overexpression downregulated β-catenin and TCF4 levels in UM-UC-3 cells (Fig. 5A). In contrast, GTF2IRD2P1 knockdown activated Wnt signaling in T24 cells (Fig. 5B). The same result was seen in the nude mouse model (Fig. 5C). Therefore, GTF2IRD2P1 may mediate Wnt signaling in BCa cells in both in vitro and in vivo experiments.

Rescue assay: pathway inhibitor can suppress the pro-carcinogenic effect of GTF2IRD2P1

Finally, IWR-1, a Wnt signaling pathway inhibitor, was used to validate the function of GTF2IRD2P1 in the evolution of BCa. We chose to add IWR-1 as a negative control and knockdown of GTF2IRD2P1 groups in T24 cells, respectively. This resulted in the groups of shNC, shNC+IWR-1, shGTF2IRD2P1, and shGTF2IRD2P1+IWR-1. CCK8 experiments showed that IWR-1 could significantly rescue the knockdown of GTF2IRD2P1 on BCa cells (Fig. 6A). Western blot analysis showed that IWR-1 not
Figure 5  The role of GTF2IRD2P1 in the regulation of BCa in the Wnt signaling pathway. (A) Western blot to detect the Wnt signaling pathway key protein expression in UM-UC-3 cells. (B) Western blot to detect the Wnt signaling pathway key protein expression in T24 cells. (C) Western blot to detect the Wnt signaling pathway key protein expression in nude mouse tumors. $p^{***} < 0.001, p^{****} < 0.0001$. BCa, bladder cancer.
only inhibited the upregulation of cyclin D1 by GTF2IRD2P1 knockdown (Fig. 6B) but also attenuated the promotion of the key protein β-catenin in the Wnt signaling pathway by the knockout of GTF2IRD2P1 (Fig. 6C). Therefore, the low expression of GTF2IRD2P1 may contribute to the growth of urinary BCa cells by activating the Wnt signaling pathway.

**DISCUSSION**

The unrestricted proliferation of cells is one of the greatest difficulties to overcome for successful tumor treatment. It is also one of the main reasons for the low survival rate of BCa (Koivisto et al., 2019). Therefore, there is an urgent need to find suitable therapeutic
targets to reduce the high mortality rate of BCa patients. There has been growing evidence in the past decade that lncRNAs play a major role in the mechanisms of pathogenesis for various carcinomas, including BCa (Li et al., 2020). We believe that GTF2IRD2P1 is a prospective target for BCa treatment. To the best of our knowledge, the involvement of lncRNA-GTF2IRD2P1 in the progression and metastasis of oral squamous carcinoma was first reported in 2015 (Zhang et al., 2015), but its role in BCa is not clear. We studied BCa and paracancerous tissues from 30 total BCa resection patients and found that GTF2IRD2P1 showed low expression in BCa tissues and differed significantly from its expression in paracancerous tissues. Furthermore, GTF2IRD2P1 knockdown significantly promoted the malignant phenotype of cell proliferation, and the overexpression of GTF2IRD2P1 suppressed the aforementioned malignant phenotype. Mechanistically, we found that cell cycle proteins Cyclin A2 and Cyclin D1 were up-regulated after GTF2IRD2P1 knockdown, as were Wnt signaling pathway proteins β-catenin and TCF4. However, the overexpression of GTF2IRD2P1 had an opposite effect. Interestingly, the Wnt signaling pathway inhibitor IWR-1 was shown to reverse the effect of GTF2IRD2P1 knockdown on the propagation of BCa cells. Furthermore, xenograft studies showed that GTF2IRD2P1 knockdown significantly promoted neoplastic growth in vivo. These results indicate that GTF2IRD2P1 may be a promising biomarker for the diagnosis and prognosis of BCa and may provide a new therapeutic target for the treatment of BCa.

The signaling pathway of Wnt crosstalk leads to a variety of cellular activities, including embryogenesis, wound healing, stem cell stability, the homeostasis of calcium and tissues, and the growth of cells (Mohammed et al., 2016). The development of mutations and epigenetic alterations in key molecules of the Wnt/β-catenin classical pathway is strongly associated with oncogenesis, progression of drug resistance, and improvements in survival. Therefore Wnt signaling components are considered to be essential indicators for the diagnosis and prognosis of cancer and may provide new therapeutic targets (Garg & Maurya, 2019). Wnt/β-catenin signaling has been widely reported to play an important role in the malignant progression of BCa (Mao et al., 2018; Yuan et al., 2017). For example, the high expression of Linc00152 promotes BCa hyperproliferation and migration mediated by the activation of the Wnt/β-catenin signaling pathway (Xian-li et al., 2019). The long non-coding RNA SNHG20 plays a role in promoting cancer in the bladder by activating the Wnt/β-catenin signaling pathway (Zhao et al., 2018). However, we have shown that GTF2IRD2P1 can inhibit the Wnt/β-catenin signaling in BCa cells and that GTF2IRD2P1 exerts its effect on carcinogenesis in BCa by inactivating the signaling pathway of Wnt/β-catenin.

There are some limitations of our work. First, there was a small clinical specimen volume, which should be increased in future studies. Secondly, although we demonstrated that the mechanism of GTF2IRD2P1 negatively regulated the Wnt signaling pathway, it’s specific role in BCa is still unclear. Therefore, its role should be further explored in future studies.
CONCLUSIONS

In summary, GTF2IRD2P1 inhibits BCa development by regulating Wnt signaling. Notably, the downregulation of GTF2IRD2P1 promotes the progression of BCa via the activation of Wnt signaling. Our findings from this study suggest that GTF2IRD2P1 may be a prospective treatment target and a biomarker of prognosis for BCa patients.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This study was supported by the Yunnan Provincial Department of Science and Technology-Kunming Medical University Joint Special Fund for Applied Foundations Key Project (2019FE001(-005)) and the Yunnan Provincial Department of Science and Technology-Kunming Medical University Joint Special Fund for Applied Foundations Project (2014FB031). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:
Yunnan Provincial Department of Science and Technology-Kunming Medical University Joint Special Fund for Applied Foundations Key Project: 2019FE001(-005).
Yunnan Provincial Department of Science and Technology-Kunming Medical University Joint Special Fund for Applied Foundations Project: 2014FB031.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Zhuo Huang conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Hongbin Gao performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Liangliang Qing conceived and designed the experiments, prepared figures and/or tables, and approved the final draft.
- Biao Wang performed the experiments, prepared figures and/or tables, collect clinical specimens, and approved the final draft.
- Chaoyong He conceived and designed the experiments, prepared figures and/or tables, collect clinical specimens, and approved the final draft.
- Ning Luo analyzed the data, prepared figures and/or tables, collect clinical specimens, and approved the final draft.
- Chuncheng Lu performed the experiments, prepared figures and/or tables, collect clinical specimens, and approved the final draft.
• Shipeng Fan analyzed the data, prepared figures and/or tables, collect clinical specimens, and approved the final draft.
• Peng Gu conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
• Hui Zhao conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.

Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
The First Affiliated Hospital of Kunming Medical University granted ethical approval to conduct research in its facilities ((2021) Lun Shen L No. 33).

Animal Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
All experiments concerning animals were carried out following the guidelines for animal experiments approved by the Laboratory Animal Ethics Committee of Kunming Medical University.

Data Availability
The following information was supplied regarding data availability:
The raw measurements, figures and images are available in the Supplemental Files.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.13220#supplemental-information.

REFERENCES
Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, Neuzillet Y, Veskimäe E, van der Heijden AG, Gakis G, Ribal MJ. 2017. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. European Urology 71(3):462–475 DOI 10.1016/j.eururo.2016.06.020.
Babjuk M. 2017. Trends in bladder cancer incidence and mortality: success or disappointment? European Urology 71(1):109–110 DOI 10.1016/j.eururo.2016.06.040.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68(6):394–424 DOI 10.3322/caac.21492.
Bunch H. 2018. Gene regulation of mammalian long non-coding RNA. Molecular Genetics and Genomics 293(1):1–15 DOI 10.1007/s00438-017-1370-9.
Carneiro BA, Meeks JJ, Kuzel TM, Scarlanti M, Abdulkadir SA, Giles FJ. 2015. Emerging therapeutic targets in bladder cancer. Cancer Treatment Reviews 41(2):170–178 DOI 10.1016/j.ctrv.2014.11.003.
Garg M, Maurya N. 2019. WNT/β-catenin signaling in urothelial carcinoma of bladder. World Journal of Nephrology 8(5):83–94 DOI 10.5527/wjn.v8.i5.83.
He A, He S, Peng D, Zhan Y, Li Y, Chen Z, Gong Y, Li X, Zhou L. 2019. Prognostic value of long non-coding RNA signatures in bladder cancer. *Aging* 11(16):6237–6251 DOI 10.18632/aging.v11i16.

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. 2016. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part B: prostate and bladder tumours. *European Urology* 70(1):106–119 DOI 10.1016/j.eururo.2016.02.028.

Knowles MA, Hurst CD. 2015. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. *Nature Reviews Cancer* 15(1):25–41 DOI 10.1038/nrc3817.

Koivisto MK, Tervahartiala M, Kennessey I, Jalkanen S, Boström PJ, Salmi M. 2019. Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. *Carcinogenesis* 40(1):84–92 DOI 10.1093/carcin/bgy154.

Lenis AT, Lec PM, Chanie K, Mshs MD. 2020. Bladder cancer: a review. *JAMA* 324(19):1980–1991 DOI 10.1001/jama.2020.17598.

Li Y, Li G, Guo X, Yao H, Wang G, Li C. 2020. Non-coding RNA in bladder cancer. *Cancer Letters* 485(9):38–44 DOI 10.1016/j.canlet.2020.04.023.

Li N, Li J, Mi Q, Xie Y, Li P, Wang L, Binang H, Wang Q, Wang Y, Chen Y, Wang Y, Mao H, Du L, Wang C. 2020. Long non-coding RNA ADAMTS9-AS1 suppresses colorectal cancer by inhibiting the Wnt/β-catenin signalling pathway and is a potential diagnostic biomarker. *Journal of Cellular and Molecular Medicine* 24(19):11318–11329 DOI 10.1111/jcmm.15713.

Liang Y, Song X, Li Y, Chen B, Zhao W, Wang L, Zhang H, Liu Y, Han D, Zhang N, Ma T, Wang Y, Ye F, Luo D, Li X, Yang Q. 2020. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis. *Molecular Cancer* 19(1):85 DOI 10.1186/s12943-020-01206-5.

Liu SY, Zhao ZY, Qiao Z, Li SM, Zhang WN. 2021. LncRNA PCAT1 interacts with DKC1 to regulate proliferation, invasion and apoptosis in NSCLC Cells via the VEGF/AKT/Bcl2/Caspase9 pathway. *Cell Transplantation* 30(5):963689720986071 DOI 10.1177/0963689720986071.

Logotheti S, Marquardt S, Gupta SK, Richter C, Edelhäuser BAH, Engelmann D, Brenmoehl J, Söhnench C, Murr N, Alpers M, Singh KP, Wolfenauer O, Heckl D, Spitschak A, Pützer BM. 2020. LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1. *Theranostics* 10(21):9620–9643 DOI 10.7150/thno.44176.

Long Y, Li H, Jin Z, Zhang X. 2021. LncRNA SLC16A1-AS1 is upregulated in glioblastoma and promotes cancer cell proliferation by regulating miR-149 methylation. *Cancer Management and Research* 13:1215–1223 DOI 10.2147/CMAR.S264613.

Mao X-W, Xiao J-Q, Li Z-Y, Zheng Y-C, Zhang N. 2018. Effects of microRNA-135a on the epithelial-mesenchymal transition, migration and invasion of bladder cancer cells by targeting GSK3β through the Wnt/β-catenin signaling pathway. *Experimental and Molecular Medicine* 50(1):e429 DOI 10.1038/emm.2017.239.

Mohammed MK, Shao C, Wang J, Wei Q, Wang X, Collier Z, Tang S, Liu H, Zhang F, Huang J, Guo D, Lu M, Liu F, Liu J, Ma C, Shi LL, Athiviraham A, He T-C, Lee MJ. 2016. Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. *Genes & Diseases* 3(1):11–40 DOI 10.1016/j.j.gendis.2015.12.004.

Nadal R, Bellmunt J. 2019. Management of metastatic bladder cancer. *Cancer Treatment Reviews* 76(1):10–21 DOI 10.1016/j.ctrv.2019.04.002.
Quan J, Pan X, Zhao L, Li Z, Dai K, Yan F, Liu S, Ma H, Lai Y. 2018. LncRNA as a diagnostic and prognostic biomarker in bladder cancer: a systematic review and meta-analysis. *OncoTargets and Therapy* **11**:6415–6424 DOI 10.2147/OTT.

Richters A, Aben KKH, Kiemeney L. 2020. The global burden of urinary bladder cancer: an update. *World Journal of Urology* **38**(8):1895–1904 DOI 10.1007/s00345-019-02984-4.

Tang Y, Tang R, Tang M, Huang P, Liao Z, Zhou J, Zhou L, Su M, Chen P, Jiang J, Hu Y, Zhou Y, Liao QJ, Zeng Z, Xiong W, Chen J, Nie S. 2020. LncRNA DNAJC3-AS1 regulates fatty acid synthase the EGFR pathway to promote the progression of colorectal cancer. *Frontiers in Oncology* **10**:604534 DOI 10.3389/fonc.2020.604534.

Tang C, Wu Y, Wang X, Chen K, Tang Z, Guo X. 2021. LncRNA MAFG-AS1 regulates miR-125b-5p/SphK1 axis to promote the proliferation, migration, and invasion of bladder cancer cells. *Human Cell* **34**(2):588–597 DOI 10.1007/s13577-020-00470-3.

Xian-li T, Hong L, Hong Z, Yuan L, Jun-yong D, Peng X, Yan-ping S, Fang Y, Nan L. 2019. Higher expression of Linc00152 promotes bladder cancer proliferation and metastasis by activating the Wnt/β-catenin signaling pathway. *Medical Science Monitor* **25**:3221–3230 DOI 10.12659/MSM.913944.

Xie H, Liao X, Chen Z, Fang Y, He A, Zhong Y, Gao Q, Xiao H, Li J, Huang W, Liu Y. 2017. LncRNA MALAT1 inhibits apoptosis and promotes invasion by antagonizing miR-125b in bladder cancer cells. *Journal of Cancer* **8**(18):3803–3811 DOI 10.7150/jca.21228.

Xu J, Yang R, Hua X, Huang M, Tian Z, Li J, Lam HY, Jiang G, Cohen M, Huang C. 2020. LncRNA SNHG1 promotes basal bladder cancer invasion via interaction with PP2A catalytic subunit and induction of autophagy. *Molecular Therapy-Nucleic Acids* **21**(D1):354–366 DOI 10.1016/j.omtn.2020.06.010.

Yuan H, Yu S, Cui Y, Men C, Yang D, Gao Z, Zhu Z, Wu J. 2017. Knockdown of mediator subunit Med19 suppresses bladder cancer cell proliferation and migration by downregulating Wnt/β-catenin signalling pathway. *Journal of Cellular and Molecular Medicine* **21**(12):3254–3263 DOI 10.1111/jcmm.13229.

Zha LF, Zhang LD, Pan HM, Ma HD. 2021. Upregulation of IncRNA NCK1-AS1 predicts poor prognosis and contributes to non-small cell lung cancer proliferation by regulating CDK1. *European Review for Medical and Pharmacological Sciences* **25**(3):1351–1357 DOI 10.26355/eurrev_202102_24843.

Zhang S, Tian L, Ma P, Sun Q, Zhang K, Guanchao W, Liu H, Xu B. 2015. Potential role of differentially expressed IncRNAs in the pathogenesis of oral squamous cell carcinoma. *Archives of Oral Biology* **60**(10):1581–1587 DOI 10.1016/j.archoralbio.2015.08.003.

Zhang L, Wu X, Li Y, Teng X, Zou L, Yu B. 2021. LncRNA SNHG5 promotes cervical cancer progression by regulating the miR-132/SOX4 pathway. *Autoimmunity* **54**(2):1–9 DOI 10.1080/08916934.2020.1864731.

Zhao Q, Gao S, Du Q, Liu Y. 2018. Long non-coding RNA SNHG20 promotes bladder cancer via activating the Wnt/β-catenin signalling pathway. *International Journal of Molecular Medicine* **42**(5):2839–2848 DOI 10.3892/ijmm.2018.3819.